TAmiRNA to present miND® NextGen sequencing insights to RNA Leaders 2023 in Boston

Vienna, Austria: Biotech and diagnostic innovator TAmiRNA will be a significant contributor to this year’s RNA Leaders Meeting in Boston, Massachusetts.

TAmiRNA will both showcase the use of its innovative oligomer-based miND® spike ins to discover novel circulating microRNA Biomarkers and will also show how these have recently been applied to identify miRNA biomarkers for clinical drug-induced organ damage.

New biomarkers

TAmiRNA CEO and co-founder Dr. Matthias Hackl will be a keynote presenter at the conference, showing how innovative scientific approaches have facilitated significant progress in (RNA) drug development.

Dr. Hackl’s Day Two presentation (September 7, 1630 hrs.) on ‘Discovery & Validation of MicroRNA Biomarkers Of Clinical Drug-Induced Organ Injury’ will review how safety and tolerability of drug candidates and newly approved drugs remain key concerns in pharma R&D, often leading to labelling restrictions, black box warnings, and withdrawal of otherwise promising innovative medicines.

TransBioLine legacy

TAmiRNA’s role within the TransBioLine project has led to discovery and validation of novel microRNA-based safety biomarkers, using the unique miND® RNA-sequencing workflow that enable absolute quantitation of RNAs in liquid biopsies.

The TAmiRNA team has been able to develop reliable safety biomarkers that indicate injury of the liver, kidneys, pancreas, blood vessels, and central nervous system for drug development purposes.

About TAmiRNA

TAmiRNA specializes in technologies for profiling levels of blood-circulating miRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis, and prognosis of disease, and as companion diagnostic tests to support treatment decisions. TAmiRNA currently commercialized hepatomiR® under the CE-IVD mark for the diagnosis of liver function in liver cancer patients.

For its work on circulating microRNAs in bone disease, TAmiRNA is receiving funding from the European Union’s Horizon 2020 research and innovation program under the MARIE SKŁODOWSKA-CURIE grant agreement no. 860898. For TAmiRNA´s work on novel drug safety biomarkers, TAmiRNA receives funding from the Innovative Medicines Initiative 2 Joint Undertaking “TransBioLine” under grant agreement No. 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. For its work on senescence-associated biomarkers, TAmiRNA is receiving funding from Eureka-Eurostars grant Ab-SENS. For its work on novel liver function biomarkers, TAmiRNA is receiving funding from the Vienna Business Agency.

More information available at: www.tamirna.com

About RNA Leaders USA Congress 2023

The RNA Leaders USA Congress is an event first hosted in 2022 by the LSX network for life science executives and dedicated to sharing knowledge concerning the rapidly expanding field of RNA-based therapeutics.

The Initial round of events included meetings in Basel, Switzerland, in Spring 2022 and in Boston in September, attracting 100+ world-class speakers and over 600+ senior leaders from around the world.

The Second RNA Leaders Congress is a two-day event opening September 6 at the Hynes Convention Center in Boston, MA.  Topics under discussion will include Antisense Technologies, Circular RNA, CRISPR, RNA & Gene Editing, Gene Therapy Approaches, lncRNA, miRNA therapeutics, mRNA vaccines, and RNA Cell Therapy,

The event is organized by LSX with further information at: https://www.lsxleaders.com/rna-leaders-usa-congress

Resources

Click on TAmiRNA MiND Next Generation Sequencing  for further information.